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Lack of both bradykinin receptors 
enhances diabetic nephropathy
Kakoki et al., Proc Natl Acad Sci USA 2010; 107: 10190–10195; doi:10.1073/
pnas.1005144107
Inhibitors of the angiotensin-converting enzyme (ACE) 
have beneficial effects in the renal disease and retinopathy of 
diabetes that cannot be reproduced by similar decreases in 
arterial pressure with other drugs. Needless to say, in addi-
tion to generating angiotensin II, ACE also converts kinins 
into inactive metabolites. Changes in levels of ACE affect the 
levels of its substrates much more than its products, so that 
small changes in ACE affect kinins more than angiotensin II. 
Indeed, a common polymorphism of the ACE gene in humans 
that results in higher plasma ACE levels does not affect arte-
rial pressure or angiotensin II. Interestingly, however, the more 
highly expressing allele is associated with an increased risk of 
diabetic complications. These findings suggested that the kal-
likrein–kinin system may partly mediate the protective effects 
of ACE inhibitors on diabetic complications and that reduced 
levels of the kinins may mediate some of the harmful effects 
of the polymorphism of the ACE gene with the more highly 
expressing allele. Recent findings show that the lack of tissue 
kallikrein or one of the bradykinin receptors, B2R, resulted in 
worse diabetic renal phenotype. To further clarify the role of the 
kallikrein–kinin system in diabetic complications, Kakoki et al. 
used mice with the Akita diabetogenic mutation in the insulin 
2 gene to examine the effect of deleting both the B1 and the B2 
bradykinin receptors on their diabetic complications. Focusing 
on the renal picture, urinary albumin excretion, already high in 
the Akita diabetic mice, markedly increased in the bradykinin 
receptor knockout–Akita mice. Similarly, the glomerular scle-
rosis (Figure) and interstitial fibrosis caused by Akita diabetes 
were enhanced markedly by lack of both receptors, as was the 
thickening of basement membrane. Thus, the diabetic neph-
ropathy in Akita mice is distinctly enhanced by lack of bradyki-
nin receptors. Moreover, absence of both bradykinin receptors 
aggravated the neuropathy and bone mineral loss of diabetes 
and also increased oxidative stress, mitochondrial mutations, 
and expression of fibrogenic genes.
These results demonstrate that B1R and B2R moderate the 
development of complications in diabetic mice and suggest that 
activation of the kallikrein–kinin system could be beneficial 
in reducing the severity of complications in diabetic patients, 
particularly those carrying the more highly expressing allele 
of the ACE gene.
Juan Oliver
A mouse line with late-onset type I 
Bartter syndrome
Kemter et al., Am J Physiol Renal Physiol 2010; 298: F1405–F1415; 
doi:10.1152/ajprenal.00522.2009
The bumetanide-sensitive Na+-K+-2Cl– cotransporter NKCC2 
is located in the apical membrane of the cells of the thick 
ascending limb of Henle’s loop, including those of the macula 
densa. Needless to say, it has critical roles in sodium balance, 
divalent mineral cation metabolism, and the kidney’s ability to 
concentrate urine. In addition, NKCC2 also influences renin 
release and tubuloglomerular feedback. In humans, loss-of-
function mutations of the solute carrier family 12 member 1 
gene (SLC12A1), which encodes NKCC2, cause type I Bartter 
syndrome, characterized by prenatal onset of a severe polyu-
ria, salt-wasting tubulopathy, and hyperreninemia. Hereditary 
diseases, including nephropathies, are caused mainly by point 
mutations leading to gene dysfunction. Mutant mouse lines har-
boring ethylnitrosourea (ENU)-induced point mutations repre-
sent suitable models to mimic hereditary disease in humans and 
to analyze the various facets of gene function and dysfunction. 
In a phenotype-driven ENU-mutagenesis approach screening 
for elevated plasma urea, several mouse lines with kidney dis-
eases were generated. In one of these lines, the mutation was 
identified within the Slc12a1 gene (line Slc12a1I299F) and results 
in a single amino acid substitution in NKCC2. Mice with com-
plete lack of NKCC2 died within the first 2 weeks of life because 
of severe renal failure and metabolic alterations; mice of the 
line Slc12a1I299F were viable. In a recent study, Kemter et al. 
report that homozygous mutants had severe polyuria, metabolic 
alkalosis, and a marked increase in plasma urea and hypermag-
nesemia, but close-to-normal plasma creatinine. In addition, 
the mice had hyperprostaglandinuria, hypotension, and osteo-
penia. Fractional excretion of urea was markedly decreased, 
and calcium and magnesium excretions were more than twice 
normal. In addition, and very unexpectedly, in contrast to 
hyperreninemia present in the human disease, the plasma renin 
concentration in homozygotes was not increased.
Thus, the mice exhibit a phenotype that shares many, but 
not all, of the phenotypic characteristics of human type I 
Bartter syndrome and may be an intriguing model to explore 
Kidneys in 12-month-old male wild-type (WT), B2R-null, BRKO, Akita, 
B2R-null-Akita, and BRKO-Akita mice. Absence of bradykinin receptors 
enhances renal histological changes in Akita diabetic mice.
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the syndrome. The surprising observation that renin is not 
increased deserves additional study.
Juan Oliver
Parenteral iron formulations 
differentially affect MCP-1, HO-1, 
and NGAL gene expression and 
renal responses to injury
Johnson et al., Am J Physiol Renal Physiol advance online publication, 26 
May 2010, doi:10.1152/ajprenal.00248.2010
Intravenous iron is an essential part of anemia treatment for 
patients with end-stage renal disease. Johnson et al. compared 
the effects of different parenteral iron preparations on both a 
cellular and an organism level. In cultured human proximal 
tubule (HK-2) cells, all iron formulations—iron sucrose (FeS), 
ferric gluconate (FeG), and ferumoxytol (FMX)—decreased 
MTT uptake at moderate doses. Viable cells take up the tracer 
MTT into their mitochondria. Decreased uptake of MTT 
therefore indicates injury to the cells. The degree to which the 
different iron preparations suppressed uptake was greatest with 
FeS, followed by FeG; FMX resulted in the least suppression. 
With the use of heme oxygenase-1 (HO-1) and monocyte che-
moattractant protein-1 (MCP-1) mRNA induction as markers 
of oxidant-stimulated signaling, FeS induced increases in the 
expression of both of these markers, whereas FMX had no 
significant effect. Similar results with respect to oxidation were 
seen when the experiments were repeated on an organism level 
with a mouse model. Additionally, cell injury was gauged in 
the mice by multiple assays, including renal cortical neutrophil 
gelatinase-associated lipocalin (NGAL) protein/mRNA lev-
els. FeG and FeS caused increases in plasma and renal cortex 
levels of NGAL, whereas FMX did not. Interestingly, pretreat-
ment with FeS significantly attenuated the severity of glycerol-
induced acute kidney injury (AKI), as denoted by a 50–60% 
reduction in blood urea nitrogen concentrations. However, 
FMX pretreatment did not attenuate the severity of this model 
of AKI. Lastly, in a model of lipopolysaccharide (LPS) loading 
to induce tumor necrosis factor-α (TNF-α), pretreatment with 
FeS and FeG sensitized the mice to LPS-driven production 
of TNF-α, as reflected by increases in plasma concentrations 
and renal cortical mRNA levels. Conversely, animals pretreated 
with FMX had the same degree of LPS responsiveness as non-
Fe-treated LPS-injected control animals.
These findings suggest a differential response to these inter-
mediate markers among iron preparations. However, these 
markers may or may not reflect clinically meaningful changes 
in patients. Recent counterintuitive lessons in anemia man-
agement demonstrated that the intermediate marker of hemo-
globin target is not correlated with the hard clinical outcome 
of survival in erythropoietin-stimulating agent (ESA) trials. 
Subsequently, the data generated here should form a founda-
tion for future studies on strategies for anemia management 
with the goal of minimizing any safety signal in the patient 
who is using both ESAs and iron.
Lynda Szczech
Coronary calcification is 
associated with lower bone 
formation rate in CKD patients not 
yet in dialysis treatment
Tomiyama et al., J Bone Miner Res 2010; 25: 499–504; doi:10.1359/
jbmr.090735
Vascular calcification is a frequent finding in chronic kidney 
disease (CKD) patients on dialysis and a strong, independent 
prognostic marker of mortality in that population. Russo et al.1 
recently described vascular calcifications in predialysis patients. 
London et al.2 reported that a dynamic bone disease is a condition 
favoring the faster development of vascular calcification in dialy-
sis patients. Tomiyama et al. evaluated the association between 
coronary artery calcification (CAC) and bone histomorphomet-
ric parameters in CKD predialysis patients assessed by multislice 
coronary tomography and by undecalcified bone biopsy. CAC 
was detected in 33 patients, and their median calcium score was 
89.7 (0.4–2299.3 Agatston units). The most frequent bone histo-
logical alterations observed included low trabecular bone volume, 
increased eroded and osteoclast surfaces, and low bone formation 
rate (BFR/BS). Multiple logistic regression analysis, adjusted for 
age, sex, and diabetes, showed that BFR/BS was independently 
associated with the presence of coronary calcification (odds ratio, 
0.15; 95% confidence interval, 0.036–0.619).
This study showed a high prevalence of CAC in asympto-
matic predialysis CKD patients. Also, there was an independent 
association of low bone formation and CAC in this population. 
These results provide evidence that low bone formation rate 
constitutes another nontraditional risk factor for cardiovas-
cular disease in CKD patients. Less incorporation of calcium 
and phosphate in ‘low-turnover’ bone is considered the main 
factor favoring the deposition/incorporation of calcium and 
phosphate into the media of the vessels (Figure).
Marc De Broe
1Am J Kidney Dis 2004; 44: 1024–1030. 2J Am Soc Nephrol 2004; 15: 1943–1951.
Less incorporation of calcium and phosphate in low-turnover bone, 
increasing their availability to the vessels. PTH, parathyroid hormone.
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Both forms of osteodystrophyin CKD 
contribute to hyperphosphatemia
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